List of Excipients in Branded Drug SELZENTRY

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ViiV Healthcare Company	SELZENTRY	maraviroc	49702-223	ALUMINUM OXIDE
ViiV Healthcare Company	SELZENTRY	maraviroc	49702-223	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
ViiV Healthcare Company	SELZENTRY	maraviroc	49702-223	CELLULOSE, MICROCRYSTALLINE

Selzentry (Maraviroc) Excipient Strategy and Commercial Opportunities

Last updated: September 22, 2026

Selzentry, the U.S. brand for maraviroc, is a mature oral CCR5 antagonist with limited but defensible commercial value. Its strongest opportunities are low-cost generic tablets, pediatric or liquid formulations, and differentiated products for treatment-experienced HIV patients. The core formulation is relatively conventional: immediate-release film-coated tablets using lactose, microcrystalline cellulose, dibasic calcium phosphate, magnesium stearate, and coating excipients. Commercial success depends less on novel excipient technology than on bioequivalence, manufacturing efficiency, global registration, and access to a small but clinically defined patient population.

What is Selzentry and how is maraviroc used?

Selzentry contains maraviroc, a small-molecule CCR5 co-receptor antagonist approved for treatment of adults and pediatric patients with CCR5-tropic HIV-1 infection in combination with other antiretroviral agents. It does not treat patients whose virus uses CXCR4 or mixed/dual tropism, so viral tropism testing is central to patient selection (FDA, 2024).

Maraviroc is administered orally in 150 mg and 300 mg tablets. The recommended dose depends on concomitant medications because maraviroc is a substrate of CYP3A and P-glycoprotein. Strong CYP3A inhibitors, inducers, and combinations with other antiretrovirals can materially change exposure (FDA, 2024).

Attribute	Selzentry / maraviroc
Active ingredient	Maraviroc
Mechanism	CCR5 antagonist
Therapeutic area	HIV-1 infection
U.S. dosage forms	Immediate-release film-coated tablets
Strengths	150 mg and 300 mg
Key selection requirement	CCR5-tropic virus
Main metabolic issue	CYP3A and P-glycoprotein interactions
U.S. approval	2007
Original sponsor	Pfizer
Commercial category	Mature, niche antiretroviral

What excipients are used in Selzentry tablets?

The U.S. prescribing information identifies a conventional tablet platform. The core tablet contains lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate anhydrous, and magnesium stearate. The film coating uses hypromellose-based coating materials with colorants and plasticizing components, including titanium dioxide and triacetin in the labeled formulation (FDA, 2024).

The formulation suggests that the product was designed for robust high-volume tablet manufacture rather than for a highly specialized delivery system.

Formulation component	Likely technical function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Low-cost, widely available; may require substitution in lactose-sensitive markets
Microcrystalline cellulose	Filler, dry binder, disintegration support	Supports direct compression and mechanical strength
Dibasic calcium phosphate anhydrous	Inorganic diluent and compression aid	Improves bulk density and tablet robustness
Magnesium stearate	Lubricant	Requires control of blending time and concentration
Hypromellose	Film-forming polymer	Supports coating integrity and swallowability
Triacetin	Plasticizer	Reduces coating brittleness
Titanium dioxide and colorants	Opacity and product identification	Relevant to jurisdictional coating compliance

The combination of lactose, microcrystalline cellulose, and dibasic calcium phosphate gives a formulation developer multiple routes to achieve comparable tablet hardness, friability, disintegration, and dissolution. That flexibility reduces the technical barrier to generic entry.

What excipient strategy is most suitable for generic maraviroc?

The lowest-risk strategy is a compositionally similar immediate-release tablet. A generic developer should prioritize dissolution matching, content uniformity, tablet robustness, and stability rather than introduce an unnecessary modified-release platform.

Maraviroc is a relatively low-dose-to-moderate-dose active ingredient within a tablet matrix that contains substantial excipient mass. The formulation program should focus on:

1. API particle-size and polymorph control.
2. Uniform distribution of the active ingredient throughout the blend.
3. Lubrication control to prevent dissolution retardation.
4. Moisture management for lactose-containing blends.
5. Film-coat compatibility and color matching.
6. Comparative dissolution across physiological pH conditions.

A direct-compression process may be attractive if the selected maraviroc grade has adequate flow and compactability. Roller compaction or wet granulation may be required if blend segregation, poor flow, or content-uniformity risk emerges during scale-up.

Lactose-free formulation opportunity

A lactose-free version could substitute mannitol, anhydrous dibasic calcium phosphate, spray-dried cellulose, silicified microcrystalline cellulose, or selected starch-based excipients. The commercial value is moderate rather than transformational. Lactose intolerance is common, but the amount of lactose in a tablet is generally not the same concern as lactose exposure from food or a high-lactose dosage form.

The stronger rationale for lactose substitution is manufacturing and market positioning:

• simplified excipient sourcing;
• access to markets with customer preference for lactose-free products;
• reduced dependence on lactose moisture behavior;
• potential improvement in patient perception;
• differentiation among otherwise interchangeable generics.

A lactose-free formulation must preserve dissolution and bioequivalence. Replacing lactose with mannitol or a high-functionality cellulose can alter tablet porosity, water penetration, hardness, and coating behavior.

Titanium-dioxide-free coating

A titanium-dioxide-free coating may support European and selected international registrations where titanium dioxide restrictions or customer policies affect pharmaceutical coatings. Alternatives include iron oxides, calcium carbonate, talc, starch-based opacifiers, or white pigment systems selected for the target jurisdiction.

This is a practical line-extension opportunity, but it is unlikely to create strong exclusivity. The value is regulatory flexibility and supply-chain simplification, not a durable barrier to competition.

What formulation patents protect Selzentry?

The principal patent value historically rested on maraviroc as a chemical entity and its therapeutic use, rather than on a complex excipient platform. The approved Selzentry dosage form is an immediate-release tablet using widely used excipients. That makes a conventional tablet formulation difficult to protect broadly with composition-of-matter claims.

Potentially protectable formulation concepts include:

• a specific particle-size distribution;
• a defined crystalline or polymorphic form;
• a narrow dissolution profile;
• a low-impurity manufacturing process;
• a pediatric liquid formulation;
• a fixed-dose combination;
• a bioavailability-enhancing composition;
• a novel taste-masking system;
• a stable amorphous dispersion or other enabling formulation.

A generic applicant can usually avoid formulation patent exposure by selecting different excipient grades, coating systems, processing parameters, or particle-size specifications, provided the resulting product meets applicable bioequivalence and quality requirements.

The relevant patent position must be assessed in each jurisdiction through the FDA Orange Book, USPTO records, WIPO Patentscope, and national registers. Orange Book listings can change over time, and patent expiry should not be inferred solely from the 2007 approval date (FDA, n.d.-a; USPTO, n.d.).

When does Selzentry lose exclusivity?

Selzentry’s U.S. regulatory exclusivity has expired. Maraviroc received FDA approval in 2007, and the five-year new chemical entity period therefore ended in 2012. Any pediatric exclusivity would have added six months to applicable exclusivity periods, but it does not create current market exclusivity for the brand.

Patent expiry is a separate question. Chemical, formulation, process, and method-of-use patents may have different expiry dates and may be subject to patent-term adjustment or extension. A complete launch analysis must distinguish:

Exclusivity type	Selzentry relevance
New chemical entity exclusivity	Expired
Pediatric exclusivity	Historical, if granted for the relevant period
Orphan exclusivity	Not the principal commercial framework
Method-of-use patents	May affect specific labeled indications or dosing claims
Formulation patents	Potentially relevant to a particular product or process
Data exclusivity outside the U.S.	Varies by jurisdiction
Patent-term extension	Must be verified patent by patent

No broad formulation barrier is apparent from the labeled excipient system. The main remaining legal risks are patent-specific, jurisdiction-specific, and tied to the exact generic product design.

What is the Orange Book status of Selzentry?

The Orange Book is the controlling U.S. source for listed patents, therapeutic-equivalence evaluations, and approved product information. Selzentry should be reviewed by active ingredient, strength, dosage form, and listed patent status rather than by brand name alone (FDA, n.d.-a).

For a potential ANDA applicant, the key questions are:

• whether an active patent is listed against the 150 mg or 300 mg tablet;
• whether the patent claims the active ingredient, formulation, method of use, or manufacturing process;
• whether a Paragraph IV certification is commercially justified;
• whether a section viii statement can omit a patented use;
• whether the reference product remains actively marketed;
• whether the generic market has sufficient volume to support filing and launch.

The economic value of a Paragraph IV challenge is constrained by the size of the maraviroc market. A patent challenge can be legally attractive while producing limited commercial returns if the addressable U.S. patient population is small.

Which companies are challenging Selzentry patents?

Publicly documented ANDA and Paragraph IV activity should be checked against current FDA litigation records and the Drug Patent Litigation Monitor. Maraviroc is not comparable to high-revenue products such as HIV combination regimens containing tenofovir, emtricitabine, bictegravir, or dolutegravir. The smaller market reduces the incentive for multiple simultaneous Paragraph IV challenges.

The absence of a highly visible challenge does not establish that no generic development is occurring. Companies may file later, pursue non-infringing formulations, or target non-U.S. markets first. Relevant potential participants include large Indian generic manufacturers, European off-patent suppliers, and contract development and manufacturing organizations with HIV portfolios.

What commercial opportunities exist for maraviroc excipients and formulations?

Generic immediate-release tablets

This is the most practical opportunity. A developer can use a conventional tablet platform and compete through:

• lower manufacturing cost;
• dual sourcing of excipients;
• lactose-free positioning;
• global strength and packaging alignment;
• reliable supply to public-sector HIV programs;
• registration in markets with limited access to CCR5 antagonists.

The main risk is volume. Maraviroc is a targeted therapy requiring tropism confirmation and is often displaced by simpler once-daily regimens.

Pediatric oral liquid

A liquid formulation is a more differentiated opportunity. Pediatric patients may have difficulty swallowing tablets, and liquid products can support weight-based dosing. Development risks include:

• poor aqueous solubility;
• chemical and physical stability;
• taste masking;
• preservative compatibility;
• dosing-device accuracy;
• interaction between suspending agents and absorption;
• supply-chain complexity.

A suspension rather than a true solution may be technically more practical. Suspending agents such as xanthan gum, hypromellose, microcrystalline cellulose-carboxymethylcellulose systems, or poloxamers could be evaluated, but each can affect redispersibility and gastrointestinal release.

Orally disintegrating or dispersible tablets

An orally disintegrating tablet could address swallowing problems without the shelf-life and microbial risks of a liquid. Mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and flavor systems are plausible development tools.

The commercial opportunity is limited by the need to demonstrate that rapid disintegration does not change exposure or introduce unacceptable taste. A dispersible tablet may be more realistic than a classic orally disintegrating tablet because maraviroc’s dose and taste profile may make complete oral disintegration challenging.

Fixed-dose combinations

A fixed-dose combination with another antiretroviral could improve adherence, but the development burden is high. Maraviroc has dose adjustments tied to CYP3A modulators, while combination partners have their own pharmacokinetic and patent constraints. The need for CCR5 tropism testing also limits the broad-market appeal of a combination product.

The strongest target would be a specialist salvage regimen rather than a first-line product.

How strong is the Selzentry patent estate?

The patent estate is stronger around the active pharmaceutical ingredient and historical use claims than around the marketed excipient system. The excipient platform contains common pharmaceutical materials and does not create a substantial formulation moat on its own.

Patent dimension	Strategic assessment
Chemical entity	Historically strong; status must be verified by jurisdiction
Basic tablet formulation	Relatively weak to moderate
Pediatric liquid	Potentially protectable if novel and clinically useful
Taste masking	Potentially protectable but difficult to enforce broadly
Manufacturing process	Moderate if it solves a specific impurity or scale-up problem
Method of use	Narrowed by CCR5 tropism and treatment context
Fixed-dose combination	Potentially valuable but commercially uncertain
Biosimilar risk	Not applicable; maraviroc is a small molecule

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

First, a standard ANDA tablet could enter after resolution of listed patent issues. This is the lowest-cost path but would face a small market and brand substitution pressure.

Second, a differentiated generic could launch with lactose-free tablets, global packaging, and both 150 mg and 300 mg strengths. This approach may improve procurement access but would not necessarily command a large premium.

Third, a specialty product could combine a pediatric liquid or dispersible tablet with regulatory filings in countries where treatment-experienced HIV populations lack convenient maraviroc access. This has higher development cost but less direct price competition.

How does maraviroc compare with competing HIV products?

Maraviroc has a narrower market than integrase inhibitors because it requires CCR5-tropism confirmation and has substantial drug-interaction management. Dolutegravir, bictegravir, and long-acting cabotegravir-based regimens generally have stronger commercial positioning in contemporary HIV treatment guidelines and formularies (DHHS, 2024).

Maraviroc retains value in selected treatment-experienced patients, particularly where resistance, tolerability, or prior treatment history limits alternatives. That supports a specialty-generic opportunity but not a mass-market excipient strategy.

What FDA regulatory pathway applies?

A conventional generic tablet would generally proceed through an ANDA under section 505(j), with the reference product used for pharmaceutical equivalence and bioequivalence. A materially different liquid, modified-release system, or novel delivery technology may require a 505(b)(2) application if it cannot fit the ANDA pathway.

The development file should emphasize:

• comparative dissolution;
• fed and fasted bioequivalence where required;
• dose proportionality across strengths;
• impurity and degradation-product control;
• excipient qualification;
• container-closure protection;
• drug-interaction labeling consistency;
• pediatric dosing and palatability data for liquid products.

Key Takeaways

• Selzentry is an immediate-release maraviroc tablet with a conventional excipient system.
• The principal formulation excipients are lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate, and magnesium stearate.
• A standard generic tablet is technically feasible and presents the lowest development risk.
• Lactose-free and titanium-dioxide-free versions offer practical regulatory and procurement differentiation.
• Pediatric liquid and dispersible tablets provide the strongest formulation-led opportunities.
• Maraviroc’s small, tropism-selected patient population limits revenue upside.
• The main commercial risk is market size, not excipient complexity.
• The active patent and Orange Book position must be confirmed patent by patent before a U.S. launch decision.
• Biosimilar competition is irrelevant because maraviroc is a small-molecule drug.
• A conventional ANDA is likely more commercially rational than a complex 505(b)(2) product unless the developer has a defined pediatric or specialty-market strategy.

FAQs

Is Selzentry still commercially relevant?

Yes, but as a niche treatment for selected CCR5-tropic, treatment-experienced HIV patients rather than as a broad first-line antiretroviral.

Can maraviroc be formulated without lactose?

Yes. Mannitol, advanced cellulose systems, starch-based fillers, and anhydrous calcium phosphate are plausible alternatives, subject to dissolution and bioequivalence requirements.

Is a maraviroc oral suspension commercially attractive?

It can be attractive for pediatric and swallowing-impaired patients, but taste masking, stability, dosing accuracy, and limited market volume increase development risk.

Does maraviroc face biosimilar competition?

No. Maraviroc is a chemically synthesized small molecule. Competition would arise through generic drug pathways, not biosimilar regulation.

What is the best excipient-led differentiation strategy for generic maraviroc?

A lactose-free, globally registrable immediate-release tablet is the lowest-risk option. A pediatric liquid or dispersible tablet offers greater differentiation but requires more substantial formulation and regulatory work.

References

1. U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. National Institutes of Health.

2. U.S. Food and Drug Administration. (2024). Selzentry (maraviroc) prescribing information. Pfizer Laboratories.

3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.-b). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/